What is Vascepa (icosapent ethyl) used for?

Vascepa is a prescription form of purified EPA omega-3, used to lower cardiovascular risk in people who are already on a statin but still have high triglycerides, and who have heart disease or diabetes with other risk factors. In its main trial it reduced cardiovascular events by about 25%. It is an add-on to a statin rather than a triglyceride pill you take on its own.

What are the side effects of Vascepa?

The most notable is atrial fibrillation, an irregular heartbeat, which was more common on the drug than on placebo. It also modestly increases the risk of bleeding, which matters if you take a blood thinner, and can cause some swelling in the legs. Many people tolerate it well, but these risks are part of the decision.

Who should consider Vascepa?

The clearest candidate is someone already taking a statin who still has elevated triglycerides, usually 150 mg/dL or higher, and who has established cardiovascular disease or diabetes with additional risk factors. That matches the population studied and approved. For someone with normal triglycerides or low overall risk, it is not indicated.

What is Vascepa (icosapent ethyl) used for?

Vascepa is a prescription form of purified EPA omega-3, used to lower cardiovascular risk in people who are already on a statin but still have high triglycerides, and who have heart disease or diabetes with other risk factors. In its main trial it reduced cardiovascular events by about 25%. It is an add-on to a statin rather than a triglyceride pill you take on its own.

What are the side effects of Vascepa?

The most notable is atrial fibrillation, an irregular heartbeat, which was more common on the drug than on placebo. It also modestly increases the risk of bleeding, which matters if you take a blood thinner, and can cause some swelling in the legs. Many people tolerate it well, but these risks are part of the decision.

Who should consider Vascepa?

The clearest candidate is someone already taking a statin who still has elevated triglycerides, usually 150 mg/dL or higher, and who has established cardiovascular disease or diabetes with additional risk factors. That matches the population studied and approved. For someone with normal triglycerides or low overall risk, it is not indicated.

Icosapent Ethyl (Vascepa): Prescription EPA for the Heart | Philadelphia

TL;DR30-second take

Icosapent ethyl, sold as Vascepa, is a prescription form of purified EPA, one of the omega-3 fats, taken at a high dose (4 grams a day). In a large trial called REDUCE-IT, it lowered cardiovascular events by about 25% in people with high triglycerides who were already on a statin, which led to FDA approval in 2019. But the picture is debated: a second big trial of a similar drug found no benefit, and REDUCE-IT used an unusual placebo that may have made the drug look better than it is. The fair read is that it probably helps a specific group, though the size of the benefit is uncertain. What is clear is that it is not the same as over-the-counter fish oil, which has not shown the same benefit.

TL;DR: Icosapent ethyl, sold as Vascepa, is a prescription form of purified EPA omega-3, taken at 4 grams a day. In the REDUCE-IT trial it lowered cardiovascular events by about 25% in statin-treated people with high triglycerides and high risk, which led to FDA approval in 2019. The catch is a live scientific debate: a second large trial of a similar drug found no benefit, and REDUCE-IT used a mineral oil placebo that may have made the drug look better than it is. Regulators judged that effect small but did not dismiss it, so the benefit likely holds up while its true size is uncertain. One point is not in doubt: prescription EPA is not the same as over-the-counter fish oil, which has failed to show the same benefit.

What is icosapent ethyl, and how is it different from fish oil?

Icosapent ethyl, sold as Vascepa, is a prescription medicine made of a purified omega-3 fat called EPA, or eicosapentaenoic acid. That purity is the point. Ordinary fish oil is a mix of two omega-3s, EPA and DHA, at modest doses and with quality that varies from bottle to bottle. Icosapent ethyl is EPA at high purity, at a much higher dose of 4 grams a day, made to pharmaceutical standards.

The EPA-only design also matters for cholesterol. DHA, the other omega-3, tends to raise LDL cholesterol, while pure EPA does not, which is one reason the drug was built without it. So while a fish oil capsule and Vascepa both come from the sea, they are different products with different evidence behind them, a distinction that turns out to be central to the whole story.

What did the REDUCE-IT trial show?

The case for icosapent ethyl rests mainly on one large trial, REDUCE-IT. It enrolled about 8,200 people who were already taking a statin but still had elevated triglycerides, along with either established heart disease or diabetes plus other risk factors. Over about five years, those given icosapent ethyl had roughly 25% fewer events in the primary composite, which counted cardiovascular death, heart attack, stroke, artery-opening procedures, and unstable angina.¹ Deaths from cardiovascular causes fell as well.

What made the result striking was that the benefit looked larger than the modest drop in triglycerides could explain. Triglycerides fell less than 20%, yet events fell much more, which suggested the drug was doing something beyond lowering that one number, perhaps stabilizing plaque or calming inflammation. On the strength of this trial, the FDA approved icosapent ethyl for cardiovascular risk reduction in 2019.

Why is there a debate?

Here is where it gets complicated, and where a careful reader deserves the full picture. A second large trial, STRENGTH, tested a similar high-dose omega-3, one that included both EPA and DHA, in a comparable population. It was stopped early because it showed no benefit at all.² That raised an obvious question: if one omega-3 trial was strongly positive and another was flatly negative, what explains the difference?

Two theories compete. The first is that the EPA-only formulation in REDUCE-IT is special, and the EPA-plus-DHA mix in STRENGTH is not. The second, more skeptical theory points to the placebos. REDUCE-IT used mineral oil as its placebo, and the people taking that placebo saw their LDL cholesterol and inflammatory markers rise, which could have made the comparison group look worse and the drug look better than it truly was. STRENGTH used a corn oil placebo that did not cause those changes, and it found nothing.

So which is it? Regulators looked hard at the mineral oil concern and judged it small, estimating it could account for only a few percentage points of the benefit rather than the whole 25%. Most guidelines went on to endorse the drug for the right patients. But the question is not fully settled, and a serious minority of experts still believe the placebo inflated the result. The fair summary is that the benefit likely holds up, while its true size is uncertain.

Who is it for, and what are the risks?

Icosapent ethyl is aimed at a specific person: someone already on a statin, with triglycerides that remain high, who has heart disease or diabetes with other risk factors. That is the group REDUCE-IT studied and the group the approval covers. It is an add-on to a statin rather than a replacement, and it does little for someone whose triglycerides are already normal.

The risks belong in the decision. The most notable is atrial fibrillation, an irregular heart rhythm, which occurred more often on the drug than on placebo (about 5% versus 4%). It also raised the risk of bleeding modestly, which matters for anyone on a blood thinner, and caused more swelling in the legs for some. None of these is common, but together they mean the choice is a careful weighing of benefit against risk, best made with a physician who knows your history.

Should you take it instead of fish oil?

This is one of the most common points of confusion, so let me state it plainly: over-the-counter fish oil supplements are not a substitute for icosapent ethyl, and the evidence for fish oil in preventing heart disease is weak. Large trials of ordinary omega-3 supplements, at the doses most people take, have failed to reduce cardiovascular events.³ ⁴

The difference comes down to purity, dose, and proof. Fish oil capsules deliver a mix of EPA and DHA at a fraction of the dose, without the pharmaceutical quality control, and without a trial showing they lower events. If your triglycerides and your risk profile point toward EPA therapy, that means a prescription for icosapent ethyl, discussed with your physician, rather than a bottle of fish oil from the drugstore shelf.

Guidance from the Clinic

"Icosapent ethyl is a drug I use, but carefully, and with the debate out in the open. For the right patient, someone on a statin whose triglycerides stay up and whose risk is high, REDUCE-IT is a serious trial with a meaningful result, and I am willing to act on it. What I will not do is oversell it. The placebo question is legitimate, the size of the benefit is uncertain, and a second big trial came up empty, so I frame it to patients as a reasonable option that carries some uncertainty rather than a sure thing. The easiest thing I can clear up is the fish oil myth: the capsule in your cabinet is not this drug, and it does not have this evidence. If EPA is right for you, it is a prescription."

Key Takeaways

Icosapent ethyl (Vascepa) is a prescription form of purified EPA omega-3, taken at 4 grams a day, and it is not the same as over-the-counter fish oil.
In the REDUCE-IT trial, it lowered cardiovascular events by about 25% in statin-treated patients with high triglycerides and high risk, leading to FDA approval in 2019.
The benefit is debated: a second trial of a similar drug was null, and REDUCE-IT's mineral oil placebo may have inflated the result, so the true size of the benefit is uncertain.
The main risks are atrial fibrillation and a modest increase in bleeding, which belong in the decision.
Over-the-counter fish oil supplements have not been shown to prevent heart disease and are not a substitute for the prescription drug.

Beyond Statins: Other Ways to Lower Cholesterol and ApoB - where icosapent ethyl fits among the options
ApoB and Heart Health - the particle count that comes first
The Omega-3 Index - measuring your omega-3 status
What Is a Preventive Cardiologist? - the decision layer around these choices
Advanced Lipid Testing in Philadelphia - measuring triglycerides and the full picture

Scientific References

Bhatt DL, Steg PG, Miller M, et al. "Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia." New England Journal of Medicine. 2019;380(1):11-23.
Nicholls SJ, Lincoff AM, Nissen SE, et al. "Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial." JAMA. 2020;324(22):2268-2280.
Manson JE, Cook NR, Lee IM, et al. "Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer." New England Journal of Medicine. 2019;380(1):23-32.
ASCEND Study Collaborative Group. "Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus." New England Journal of Medicine. 2018;379(16):1540-1550.

Fishtown Medicine | Cardiovascular risk

2418 E York St, Philadelphia, PA 19125(267) 360-7927 hello@fishtownmedicine.comHSA/FSA Eligible

Start your intake

Frequently Asked Questions

Common Questions

No, and this is the most important distinction. Vascepa is purified EPA at a high prescription dose, made to pharmaceutical standards, with a trial behind it. Over-the-counter fish oil is a lower-dose mix of EPA and DHA with variable quality, and large trials of such supplements have not shown they prevent heart disease. You cannot substitute drugstore fish oil for Vascepa and expect the same effect.

In one large trial, REDUCE-IT, it lowered a composite of cardiovascular events, including heart attacks, by about 25% in high-risk, statin-treated patients with high triglycerides. That result led to FDA approval. However, a second trial of a similar drug found no benefit, and there is a legitimate debate about whether the placebo used in REDUCE-IT made the effect look larger. So the benefit likely holds up but its true size is uncertain.

Deep-Dive Questions

The two trials reached opposite conclusions, and the reason is still debated. REDUCE-IT tested pure EPA and was strongly positive; STRENGTH tested a mix of EPA and DHA and found nothing.12 One explanation is that pure EPA is truly different and better. The other is that the trials used different placebos: REDUCE-IT's mineral oil appeared to worsen cholesterol and inflammation in the comparison group, which could inflate the apparent benefit, while STRENGTH's corn oil did not. Both explanations have serious support, which is why the field has not fully closed the question.

This is the heart of the controversy. In REDUCE-IT, the group taking the mineral oil placebo saw their LDL cholesterol and inflammatory markers rise, which would make the drug look better by comparison. Critics argue this could account for much of the benefit. Regulators examined it closely and concluded the effect was small, likely explaining only a few percentage points of the 25% reduction rather than the bulk of it. The fair position today is that the mineral oil probably inflated the result somewhat, but does not erase it.

Probably not mainly. Although it does lower triglycerides, the reduction in events in REDUCE-IT was larger than that drop would predict, and other drugs that lower triglycerides have not produced the same benefit. That points to other actions of EPA, such as stabilizing the membranes of cells, reducing inflammation, and making plaque less likely to rupture. These mechanisms are plausible and under study, though none is proven to be the reason it works.

For preventing heart disease, the evidence is weak. Large trials of ordinary omega-3 supplements have not reduced cardiovascular events in the general population.34 Fish oil may still have a place for very high triglycerides as a triglyceride-lowering measure, or as part of a diet that includes fish, but taking a daily capsule expecting it to protect your heart is not supported by the strong trials. If heart protection is the goal and EPA is indicated, the prescription version is the one with evidence.

Ready when you are